Q&A with Dr. Norah Crossnohere: Studying Patient Preferences on Multi-Cancer Early Detection Tests
Multi-cancer early detection (MCED) tests are promising new screening tools that use a single patient blood sample to look for markers of many different types of cancer. Their goal is to identify the presence of cancer in the early stages when it’s more treatable, thus improving chances of survival. In addition, MCED tests have the potential to improve health equity by increasing access to cancer screening for underserved populations that may have limited access to traditional screening methods.
Because MCED tests are still relatively new, more research is needed to evaluate their effectiveness and value to optimize their use in the health care system. Norah Crossnohere, PhD, assistant professor at the Ohio State University College of Medicine, received a 2023 PhRMA Foundation Faculty Starter Grant in Value Assessment-Health Outcomes Research for her research measuring patient preferences on MCED tests. Her work will include examining preferences across different racial groups to help advance equitable use of these tools.
Watch this video to learn about Crossnohere and her research.
Subscribe to our Blog!
The PhRMA Foundation's blog brings you the latest developments in health care value assessment.